

Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

Amber A. DeVries, PhD,^{1,†,‡} Joe Dennis, MSc ,^{2,†} Jonathan P. Tyrer, PhD,^{3,†} Pei-Chen Peng, PhD,¹ Simon G. Coetzee,¹ Alberto L. Reyes, BS,¹ Jasmine T. Plummer, PhD ,^{1,4} Brian D. Davis, BS,^{1,4} Stephanie S. Chen, BS,^{1,4} Felipe Segato Dezem, BS,¹ Katja K. H. Aben, PhD,^{5,6} Hoda Anton-Culver, PhD ,⁷ Natalia N. Antonenkova, MD,⁸ Matthias W. Beckmann, MD,⁹ Alicia Beeghly-Fadiel, PhD,¹⁰ Andrew Berchuck, MD,¹¹ Natalia V. Bogdanova, PhD,^{8,12,13} Nadja Bogdanova-Markov, MD, PhD,¹⁴ James D. Brenton, MD,¹⁵ Ralf Butzow, MD, PhD,¹⁶ Ian Campbell, PhD ,^{17,18} Jenny Chang-Claude, PhD,^{19,20} Georgia Chenevix-Trench, PhD ,²¹ Linda S. Cook, PhD,^{22,23} Anna DeFazio, PhD,^{24,25,26} Jennifer A. Doherty, MS, PhD,²⁷ Thilo Dörk, PhD,¹³ Diana M. Eccles, MD,²⁸ A. Heather Eliassen, ScD ,^{29,30,31} Peter A. Fasching, MD,^{9,32} Renée T. Fortner, PhD,¹⁹ Graham G. Giles, PhD,^{33,34,35} Ellen L. Goode, PhD, MPH,³⁶ Marc T. Goodman, PhD,³⁷ Jacek Gronwald, MD, PhD,³⁸ OPAL Study Group, AOCs Group, Niclas Håkansson, PhD,⁴⁰ Michelle A. T. Hildebrandt, PhD,⁴¹ Chad Huff, PhD,⁴¹ David G. Huntsman, MD,^{42,43} Allan Jensen, PhD ,⁴⁴ Siddhartha Kar, PhD ,^{45,46} Beth Y. Karlan, MD,⁴⁷ Elza K. Khusnutdinova, MD,^{48,49} Lambertus A. Kiemeny, PhD,⁵ Susanne K. Kjaer, MD, DMSc,^{44,50} Jolanta Kupryjanczyk, MD, PhD,⁵¹ Marilyne Labrie, PhD,⁵² Diether Lambrechts, PhD,^{53,54} Nhu D. Le, PhD,⁵⁵ Jan Lubiński, MD, PhD,³⁸ Taymaa May, MD,⁵⁶ Usha Menon, MD ,⁵⁷ Roger L. Milne, PhD,^{33,34,35} Francesmary Modugno, PhD, MPH,^{58,59} Alvaro N. Monteiro, PhD,⁶⁰ Kirsten B. Moysich, MS, PhD,⁶¹ Kunle Odunsi, MD, PhD,^{62,63} Håkan Olsson, MD, PhD,⁶⁴ Celeste L. Pearce, PhD,^{65,66} Tanja Pejovic, MD, PhD,^{54,67} Susan J. Ramus, PhD,^{68,69} Elio Riboli, PhD ,⁷⁰ Marjorie J. Riggan, BSc,¹¹ Isabelle Romieu, MS, PhD, ScD,⁷¹ Dale P. Sandler, PhD,⁷² Joellen M. Schildkraut, PhD,⁷³ V. Wendy Setiawan, PhD,⁷⁴ Weiva Sieh, MD, PhD ,^{75,76} Honglin Song, PhD,⁷⁷ Rebecca Sutphen, MD,⁷⁸ Kathryn L. Terry, ScD,^{30,79} Pamela J. Thompson, MPH,³⁷ Linda Titus, PhD,⁸⁰ Shelley S. Tworoger, PhD,⁶⁰ Els Van Nieuwenhuysen, PhD,⁸¹ Digna Velez Edwards, PhD, MS,⁸² Penelope M. Webb, PhD ,³⁹ Nicolas Wentzensen, MD, PhD ,⁸³ Alice S. Whittemore, PhD,^{84,85} Alicja Wolk, DrMedSci ,^{40,86} Anna H. Wu, PhD,⁶⁶ Argyrios Ziogas, PhD ,⁷ Matthew L. Freedman, MD,⁸⁷ Kate Lawrenson, PhD ,⁸⁸ Paul D.P. Pharoah, PhD,^{2,3,3} Douglas F. Easton, PhD,^{2,3,3} Simon A. Gayther, PhD,^{1,8} Michelle R. Jones, PhD ,^{1,*,§}

¹Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; ²Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; ³Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK; ⁴Applied Genomics, Computation and Translational Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA; ⁵Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; ⁶Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; ⁷Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA; ⁸N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus; ⁹Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany; ¹⁰Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA; ¹¹Department of Gynecologic Oncology, Duke University Hospital, Durham, NC, USA; ¹²Department of Radiation Oncology, Hannover Medical School, Hannover, Germany; ¹³Gynaecology Research Unit, Hannover Medical School, Hannover, Germany; ¹⁴Institute of Human Genetics, University of Münster, Münster, Germany; ¹⁵Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK; ¹⁶Department of Pathology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland; ¹⁷Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia; ¹⁸Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia; ¹⁹Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; ²⁰Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany;

Received: January 28, 2022; Revised: April 13, 2022; Accepted: August 18, 2022

© The Author(s) 2022. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

²¹Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; ²²Epidemiology, School of Public Health, University of Colorado, Aurora, CO, USA; ²³Community Health Sciences, University of Calgary, Calgary, AB, Canada; ²⁴Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia; ²⁵Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia; ²⁶The Daffodil Centre, a joint venture with Cancer Council NSW, The University of Sydney, Sydney, New South Wales, Australia; ²⁷Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA; ²⁸Faculty of Medicine, University of Southampton, Southampton, UK; ²⁹Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; ³⁰Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; ³¹Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; ³²David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA; ³³Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia; ³⁴Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia; ³⁵Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; ³⁶Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA; ³⁷Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA; ³⁸Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; ³⁹Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; ⁴⁰Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; ⁴¹Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁴²Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada; ⁴³Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada; ⁴⁴Department of Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark; ⁴⁵Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK; ⁴⁶Section of Translational Epidemiology, Division of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; ⁴⁷David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA; ⁴⁸Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia; ⁴⁹Saint Petersburg State University, Saint Petersburg, Russia; ⁵⁰Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; ⁵¹Department of Pathology and Laboratory Diagnostics, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; ⁵²Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; ⁵³VIB Center for Cancer Biology, VIB, Leuven, Belgium; ⁵⁴Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; ⁵⁵Cancer Control Research, BC Cancer, Vancouver, BC, Canada; ⁵⁶Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada; ⁵⁷MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK; ⁵⁸Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA; ⁵⁹Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ⁶⁰Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA; ⁶¹Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA; ⁶²Department of Oncology, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA; ⁶³Department of Obstetrics and Gynecology, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA; ⁶⁴Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden; ⁶⁵Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; ⁶⁶Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA; ⁶⁷Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, USA; ⁶⁸School of Women's and Children's Health, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia; ⁶⁹Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia; ⁷⁰Imperial College London, London, UK; ⁷¹Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC-WHO), Lyon, France; ⁷²Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA; ⁷³Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; ⁷⁴Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ⁷⁵Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁷⁶Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁷⁷Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; ⁷⁸Epidemiology Center, College of Medicine, University of South Florida, Tampa, FL, USA; ⁷⁹Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; ⁸⁰Muskie School of Public Policy, Public Health, Portland, ME, USA; ⁸¹Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Leuven Cancer Institute, Leuven, Belgium; ⁸²Division of Quantitative Sciences, Department of Obstetrics and Gynecology, Department of Biomedical Sciences, Women's Health Research, Vanderbilt University Medical Center, Nashville, TN, USA; ⁸³Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA; ⁸⁴Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA; ⁸⁵Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA; ⁸⁶Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; ⁸⁷Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; and ⁸⁸Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Women's Cancer Program at the Samuel Oschin Cancer Institute Cedars-Sinai Medical Center, Los Angeles, CA, USA

†Authors contributed equally to this work.

‡Expected degree PhD to be conferred September 2022.

§Jointly directed the study.

*Correspondence to: Michelle R. Jones, PhD, Center for Bioinformatics & Functional Genomics, Cedars-Sinai Medical Center, 8700 Beverly Blvd, SSB189, Los Angeles CA 90036, USA (e-mail: michelle.jones@csmc.edu).

Abstract

Background: Known risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort. **Methods:** Single nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer-related cell types. **Results:** We identified statistically significant risk associations with CNVs at known EOC risk genes; *BRCA1* ($P_{\text{EOC}} = 1.60\text{E-}21$; $\text{OR}_{\text{EOC}} = 8.24$), *RAD51C* ($P_{\text{high-grade serous ovarian cancer [HGSOC]}] = 5.5\text{E-}4$; odds ratio $[\text{OR}]_{\text{HGSOC}} = 5.74$ del), and *BRCA2* ($P_{\text{HGSOC}} = 7.0\text{E-}4$; $\text{OR}_{\text{HGSOC}} = 3.31$ deletion). Four suggestive associations ($P < .001$) were identified for rare CNVs. Risk-associated CNVs were enriched ($P < .05$) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types. **Conclusions:** CNVs in *BRCA1* have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at *BRCA2* and *RAD51C* gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.

Table 1. Study participant age and copy number variant distributions^a

Statistical category	Controls (n = 17 306)	EOC cases (n = 13 071)	HGSOC cases (n = 8679)	P _{EOC}	P _{HGSOC}
Mean age (range)	56.1 (18-97)	58.9 (16-93)	60.1 (18-93)	<.001	<.001
CNV segments, No. (%)					
All	91 674	69 056	46 831	—	—
Deletions	46 637 (50.9)	35 165 (50.9)	23 900 (51.0)	—	—
Duplications	45 037 (49.1)	33 891 (49.1)	22 931 (49.0)	—	—
CNV segments, mean					
All	5.3	5.3	5.3	.59	.68
Deletions	2.7	2.7	2.7	.78	.83
Duplications	2.6	2.6	2.6	.63	.44
Median CNV length, kb					
All	22.2	21.9	21.4	.57	.91
Deletions	13.7	13.4	13.5	.68	.77
Duplications	37.1	36.7	36.1	.64	.87
Mean CNV length, kb					
All	67.4	67.8	67.3	.57	.91
Deletions	44.6	44.9	44.8	.68	.77
Duplications	91.0	91.6	90.8	.64	.87

^aCNV = copy number variant; EOC = epithelial ovarian cancer; HGSOC = high-grade serous ovarian cancer.

Epithelial ovarian cancer (EOC) has a complex genetic architecture. Genetic risk alleles include highly penetrant pathogenic mutations in the *BRCA1* and *BRCA2* genes (1); rare mutations in moderately penetrant risk genes including *BRIP1*, *RAD51D*, *RAD51C*, *FANCM*, and *PALB2* (2-5); and many common, low-risk polymorphisms identified by genome-wide association studies (GWAS) (6-17). The lifetime risk for ovarian cancer is 1.4% in the general population of the United States, however, this is greatly increased in carriers of deleterious mutations in *BRCA1* and *BRCA2* (44% and 17% lifetime risk, respectively) (18). The presence of a *BRCA1* or *BRCA2* mutation remains the strongest genetic risk factor for predicting a woman's risk of EOC and is now routinely used to guide clinical interventions, including highly effective prevention by risk-reducing surgery. The genetic risk alleles for EOC identified so far account for approximately 40% of the heritability, suggesting there are many genetic risk alleles yet to be discovered (19).

The human genome harbors approximately 5000 to 10000 structural variants (SVs), including deletions, duplications, insertions, and inversions, estimated to impact up to 13% of the human genome (20-22). By comparison, single nucleotide polymorphisms (SNPs) are estimated to affect approximately 0.1% of the human genome; thus, the estimated proportion of the human genome under structural variation is far higher than that due to SNPs. Despite this, copy number variants (CNVs; deletions and duplications) have not been analyzed at a similar scale as SNP variation, because of the cost of whole genome sequencing and technical challenges calling CNVs from genotyping arrays.

Previous studies have reported CNVs that contribute to the disease risk of other complex diseases such as breast cancer, pancreatic cancer, and diabetes (23-32). Similar extensive studies have not been performed in EOC cases, in part because of difficulty identifying large genotyped EOC case-control populations that can detect rare CNVs with sufficient power (33). Two previous genome-wide CNV analyses in approximately 1000 EOC cases and approximately 3000 unaffected controls failed to identify CNVs associated with disease risk or survival after multiple testing correction (34,35). In the current study, we have used genome-wide genotyping data from 13071 EOC cases, including 8679 high-grade serous ovarian cancer (HGSOC) cases

and 17306 controls to identify CNVs throughout the genome and evaluate their associations with EOC risk.

Methods

Participants

The Ovarian Cancer Association Consortium (OCAC) collated and genotyped blood-derived DNA on the Illumina Infinium OncoArray as previously described (6). We selected 13071 cases and 17306 controls of White European ancestry from OCAC studies within countries with both cases and controls that passed genotyping quality control measures previously described (6). All participants signed an informed consent approved by the institutional review board of the recruiting institution. Demographics for these participants and their CNV distributions are listed in [Supplementary Table 1](#) (available online) and [Table 1](#).

CNV Calling Method

The CamCNV pipeline was used to call rare CNVs from the log R ratio (LRR) intensity measurements for each OncoArray probe (36). Principal component analysis adjustment was applied to the LRR for each OCAC study to mitigate the impact of technical batch effects. We excluded outlier probes based on LRR residual. Remaining CNV calls after additional quality control exclusions (see [Supplementary Methods](#), available online) were lifted into hg38 from hg19 for downstream analysis, using University of California, Santa Cruz, Genome Browser liftOver.

Rare CNVs Association Analysis

A likelihood ratio test was performed to test for association with deletions or duplications at each probe where CNVs were observed in at least 0.05% of samples. For downstream enrichment analysis, we used probes covered by at least 5 CNVs (20981 probes with deletions only, 30917 with duplications only, and 5515 with deletions and duplications). Individual copy number variants were assigned the minimum *P* value of any probes they overlapped.

Gene burden analysis was performed by assigning probes to a single protein coding gene in the University of California, Santa Cruz, Genome Browser's knownGene table. Gene burden analyses were performed using the rare admixture maximum likelihood test (RAML) on genes with at least 5 samples carrying a CNV (37). The Bonferroni correction based on the number of genes tested in RAML for deletions, duplications, and both types of CNVs combined was a P value less than $6.37E-6$ for all EOC and a P value less than $7.07E-6$ for HGSOC. Because the smallest exact P value in our RAML analysis was a P value less than $1.0E-6$, we additionally performed a binomial test using the frequencies of CNVs in cases and controls within BRCA1 to obtain a more precise P value.

GWAS and Transcriptome-Wide Association Study Enrichment Analysis

Enrichment of CNVs at known EOC risk loci was performed at known genome-wide statistically significant loci from the most recent GWAS of EOC and HGSOC (Coetzee S, Dareng EO, Peng P-C, Rosenow W, Tyrer JP, Chen S, et al, *In Review*) and genes identified by transcriptome-wide association (TWAS) studies by Gusev et al. (38) and Lu et al. (39). Analysis was performed twice; with CNVs overlapping BRCA1 included and then excluded. Genes at GWAS genome-wide statistically significant loci and TWAS genes ($n = 37$) were mapped to linkage disequilibrium (LD) blocks from the 1000 Genomes (1000G) European subpopulation (40) and CNVs intersecting these LD blocks retained for analysis. Enrichment was performed using a foreground of CNVs associated with EOC containing 1 or more probes with a P value less than .05 in association analyses. The foreground was used to generate a 1000-fold randomly selected background. Enrichment analysis was performed in R using FunciVar (41,42).

Functional Annotation and Noncoding Enrichment Analysis

Functional biofeatures for 18 cell lines related to ovarian cancer or with shared biological features of candidate precursor cell types (Supplementary Table 3, available online) were collated for enrichment analysis. Individual samples were processed and analyzed as previously described (42,43) and are described in detail in the Supplementary Methods (available online). Enrichment was performed with FunciVar (42), using a foreground of noncoding CNVs associated with EOC and/or HGSOC and a 1000-fold randomly selected set of regions as a background. Using these 2 lists, FunciVar then intersects each variant with functional annotations, which in this analysis were our ChromHMM states lifted into hg38. The significance of results is reported as probability that foreground variants have more overlaps with the functional annotation than background regions.

Common CNVs Tagged by SNPs

A list of SNPs in high LD (≥ 0.8) with common CNVs identified in 1000G (44) were looked up in the most recent EOC and HGSOC GWAS (Coetzee S, Dareng EO, Peng P-C, Rosenow W, Tyrer JP, Chen S, et al, *In Review*). We applied a Bonferroni threshold to identify CNV-tagging SNPs that were statistically significantly associated within the nonmucinous EOC GWAS analysis, which includes all invasive subtypes except for the mucinous histotype. SNPs were considered statistically significant with a P value less than $2.09E-6$.

Results

Rare CNVs at Known EOC Susceptibility Gene Loci

We identified 160730 CNV segments, with an average of 5.3 CNVs detected in each study participant. The median deletion size was 13.6 kb, and the median duplication size was 37.0 kb (Table 1). Rare CNVs retained for analysis ranged from 0.003% to 2.95% frequency (Table 1). More than 49% of deletions and 30% of duplications in our dataset overlapped ($\geq 90\%$ of length) with a rare CNV identified in women of European descent in the 1000G. Gene burden analysis was performed for all EOC cases and in HGSOC cases separately (Bonferroni corrected significance thresholds $P \leq 6.37E-6$ and $P \leq 7.07E-6$, respectively). In both analyses, the most statistically significant risk gene was BRCA1 ($P_{\text{EOC}} < 1.0E-6$, odds ratio [OR]_{EOC} = 8.24; $P_{\text{HGSOC}} < 1.0E-6$, OR_{HGSOC} = 7.29; Table 2; Supplementary Tables 4 and 5, available online). We identified 65 cases and 5 controls predicted to be hemizygous for a deletion, and 40 cases and 12 control participants with predicted duplications; 105 of 13071 (0.80%) EOC cases, 93 of 8679 (1.1%) HGSOC cases, and 17 of 17306 (0.098%) controls harbored a predicted deletion or duplication of BRCA1 ($P = 1.60E-21$). Deletions and duplications at the BRCA1 locus are illustrated in Figure 1, A. The most common CNV we found in BRCA1 is a duplication at exon 13, a known relatively common CNV also called BRCA1-ins6kbEx13 described in Mazoyer et al. (45). This duplication is found in 20 cases and 0 controls. The most common deletion in BRCA1 in our data is found in exon 22, where a common deletion is known in families from the Netherlands (46). This was found in 10 cases, 5 of which are from the Netherlands (2.3% of all Netherlands cases have this specific CNV). The most common CNV in BRCA2 was a previously reported (47) deletion of exons 14-16, found in 4 cases in our study.

We found evidence of CNV EOC risk associations spanning 2 additional known ovarian cancer susceptibility gene regions: RAD51C ($P_{\text{EOC}} = 7.0E-4$, OR_{EOC} = 5.63; $P_{\text{HGSOC}} = 4.33E-4$, OR_{HGSOC} = 4.64) and BRCA2 (deletions only; $P_{\text{EOC}} = 0.0062$, OR_{EOC} = 4.31; $P_{\text{HGSOC}} = 7.0E-4$, OR_{HGSOC} = 3.31; Table 2). Risk associations were stronger in HGSOC, consistent with previous studies of these genes (Table 2; Figure 1, B and C) (48,49). In addition, we found evidence of association for 12 genes not previously associated with EOC risk ($P < .002$; Table 2) including PRKAGG, a cAMP-dependent protein kinase catalytic subunit gamma at 9q21.11 associated with a decreased risk in all EOC cases ($P < \text{EOC} = 5.67E-4$, OR_{EOC} = 0); the filamin-binding LIM protein 1 (FBLIM1) gene locus at 1p36.21 associated with increased risk in all EOC cases ($P_{\text{EOC}} = 8.50E-4$, OR_{EOC} = Not Available [NA]); and ARHGAP24 at 4q21.23, where both deletions and duplication were associated with an increased risk for HGSOC ($P = .00140$, OR_{HGSOC} = 3.97; Table 2).

Rare CNV Association Analysis

To detect associations with individual CNVs, we restricted analyses to probes intersecting deletions or duplications with a frequency of at least 0.05% of samples ($n = 16$ for EOC, $n = 13$ for HGSOC). There were 6882 probes with deletions, and 9778 probes with duplications were analyzed. We identified 16 CNVs associated with risk for EOC or HGSOC (Table 3; Figure 2). Some individual deletions and duplications within BRCA1 are frequent enough to appear in this analysis, and they are the only CNVs with P values below a significance threshold corrected for multiple testing. Outside of the BRCA1 locus, the most statistically significant deletion falls within the long noncoding LINC01194




Figure 1. CNVs identified at the BRCA1, BRCA2, and RAD51C susceptibility gene risk loci in EOC cases and controls. CNVs of varying size predicting deletions (horizontal red bars) and duplications (horizontal blue bars) in EOC cases (solid bars) and controls (faint bars) at the (A) BRCA1, (B) BRCA2, and (C) RAD51C gene loci. The location of all probes genotyped on the Illumina OncoArray and used to “call” copy number variations are shown as vertical blue lines. CNV = copy number variants.

also known as Cancer Testis Antigen 49 ($n = 137$; $P = .0007$). The strongest novel duplication result ($n = 90$; $P = .0003$) falls within the seventh intron of the *DCDC2* gene.

CNV Enrichment at Risk Loci Identified by GWAS and TWAS

Statistically significant CNVs intersected LD blocks at EOC GWAS risk regions at 7 of 27 EOC risk loci, even when *BRCA1* CNVs were excluded ($P < .05$; Table 4; Supplementary Tables 8 and 9, available online). HGSC histotype-specific GWAS regions were also statistically significantly enriched for risk CNVs; statistically significant CNVs intersected 12 of 30 loci ($P < .05$; Table 4; Supplementary Table 8, available online). GWAS risk regions with a statistically significant enrichment for CNVs intersected both known and potentially novel causal genes. CNVs identified in all EOC cases

were statistically significantly enriched within the bodies of TWAS genes in EOC but not HGSC (Supplementary Table 9, available online), and the regions defined by LD blocks around the same TWAS genes were not statistically significantly enriched for CNVs in either EOC or HGSC.

EOC Risk Associations for Common CNVs

To identify common CNVs associated with EOC and HGSC risk, we used tag SNPs ($r^2 > 0.8$) for common CNVs in participants of European descent ($>1\%$ frequency). We evaluated 23 960 SNPs tagging 3681 CNVs in the largest GWAS dataset for EOC and HGSC risk (Supplementary Table 10, available online). We identified 4 statistically significant SNPs tagging 4 CNVs at 2 loci ($P < 2.09E-6$) in both the EOC (excludes mucinous EOC) and the HGSC histotype-specific GWAS (Figure 2, Table 5). At 9p22.2, the risk-associated

Table 2. Gene burden testing results for rare CNVs in all EOC or HGSOC cases with a P value less than .002

Gene	No. of cases	No. of HGSOC	No. of controls	OR _{EOC}	OR _{HGSOC}	CNV type ^a	All cases P	HGSOC cases P
BRCA1	40	35	12	4.42	3.87	Duplication	<1.00E-06	<1.00E-06
BRCA1	65	58	5	17.29	15.42	Deletion	<1.00E-06	<1.00E-06
RAD51C	17	14	4	5.63	4.64	Both	7.00E-04	4.33E-04
RAD51C	14	13	3	6.18	5.74	Deletion	6.00E-03	5.50E-04
PRKACG	0	0	15	0.00	0.00	Duplication	5.67E-04	9.00E-03
BRCA2	13	10	4	4.31	3.31	Deletion	6.20E-03	7.00E-04
FBLIM1	11	6	0	NA	NA	Deletion	8.50E-04	4.80E-03
HAS3	12	10	5	3.18	2.65	Duplication	1.13E-02	1.20E-03
ARHGAP24	12	9	3	5.30	3.97	Both	1.39E-02	1.40E-03
LSP1	35	27	20	2.32	1.79	Both	2.41E-02	1.40E-03
SNX29	8	5	1	10.60	6.62	Duplication	1.40E-03	7.70E-03
PIP5K1B	1	0	20	0.07	0.00	Both	1.53E-03	2.73E-02
ALKBH4	6	2	0	NA	NA	Duplication	1.65E-03	NA
LRWD1	6	2	0	NA	NA	Duplication	1.65E-03	NA
LSP1	33	26	17	2.57	2.03	Duplication	2.31E-02	1.70E-03
TLL2	8	3	1	10.60	3.97	Duplication	1.80E-03	3.29E-02
NAT1	8	6	2	5.30	3.97	Deletion	1.90E-03	6.00E-03

^aCombined duplications and deletions P value result included only if it was more statistically significant than deletions or duplications alone. CNV = copy number variant; EOC = epithelial ovarian cancer; HGSOC = high-grade serous ovarian cancer; OR = odds ratio; NA = Not Available.

Table 3. CNVs statistically significantly associated with EOC and HGSOC with a P value less than .005

Chr	CNV region start	CNV region end	Type	No. sig probes	Probe location	OR _{EOC}	P _{EOC}	EOC Carrier count	OR _{HGSOC}	P _{HGSOC}	HGSOC carrier count
17	43 080 276	43 082 575	Duplication	7	BRCA1 coding	NA ^a	9.72E-10	26	NA ^a	1.02E-11	23
17	43 049 093	43 125 836	Deletion	6	BRCA1 coding	28.6	2.57E-07	20	33.22	5.38E-07	16
6	24 221 271	24 221 660	Duplication	3	DCDC2 intronic	0.45	3.65E-04	90	0.53	9.69E-03	84
5	12 692 574	12 726 378	Deletion	7	LINC01194 LncRNA	0.53	7.22E-04	137	0.59	9.90E-03	126
9	69 064 550	69 225 129	Duplication	6	FXN, TJP2 coding	0.19	1.48E-03	24	0.19	5.51E-03	23
17	1 197 175	1 198 288	Deletion	4	ABR intronic	0.62	2.50E-03	188	0.63	9.71E-03	168
9	116 713 991	116 729 732	Deletion	4	ASTN2 coding	3.53	2.55E-03	26	3.36	9.74E-03	19
23	67 910 806	67 923 215	Duplication	3	Intergenic	2.7	3.38E-03	40	2.32	3.07E-02	30
11	1 841 637	1 886 457	Duplication	5	LSP1 intronic	2.46	4.66E-03	44	3.1	7.68E-04	31
2	50 669 275	50 697 220	Deletion	5	NRXN1 intronic	2.93	5.14E-03	30	3.32	3.74E-03	25
12	115 341 220	115 341 234	Deletion	3	Intergenic	0.3	6.58E-03	28	0.18	3.11E-03	25
10	82 776 430	82 797 323	Deletion	4	NRG3 intronic	3.91	7.09E-03	21	4.44	4.33E-03	18
9	12 350 523	12 443 586	Deletion	11	Intergenic	2.33	1.14E-02	40	3.01	1.68E-03	36
23	36 457 791	36 541 981	Duplication	4	Intergenic	0.38	1.23E-02	34	0.15	8.57E-04	28
6	168 031 413	168 196 562	Duplication	37	KIF25, FRMD1	0.85	3.81E-02	753	0.76	1.93E-03	628
1	195 862 228	195 905 802	Deletion	10	Intergenic	1.43	5.66E-02	119	1.83	2.18E-03	110

^aNA: This deletion was only observed in cases; odds ratio (OR) could not be calculated. CNV = copy number variant; EOC = epithelial ovarian cancer; HGSOC = high-grade serous ovarian cancer.

CNV lies between *BNC2* and *CNTLN*, intersecting the promoter of a long noncoding RNA and the previously identified risk SNPs for EOC (50). The CNVs at 17q21.31 are within a common inversion polymorphism also associated with a microdeletion syndrome and predicted to disrupt *LINC02210-CRHR1*, *MAPT*, and *KANSL1* (51,52).

CNVs Are Enriched in Active Regulatory Elements in Ovarian Cancer–Related Cell Types

We identified 1707 and 1948 CNVs within nonprotein-coding DNA regions associated with EOC or HGSOC risk, respectively ($P < .05$; Supplementary Tables 6 and 7, available online). We evaluated the enrichment of these CNVs in chromatin states (weak promoter, active promoter, active region, active

enhancer, weak enhancer, insulator, and transcribed) mapped in 18 ovarian cancer–related cell types (Supplementary Table 3, available online) (Plummer JT, Dezem FS, Davis B, Chen S, Seo J-H, Giambartolomei C et al, *In Review*). We identified statistically significant enrichment of EOC risk CNVs in insulators and modest enrichment at weak promoters (Figure 3); depletion in active promoters; and enhancers (Supplementary Figure 1, Supplementary Table 11, available online). Restricting the analysis to HGSOC risk CNVs to HGSOC showed a similar pattern of enrichment (Supplementary Figure 2, available online).

Discussion

In this study, we used genome-wide genotype array probe signal intensity data for more than 13 000 EOC cases and more than




Figure 2. A) Manhattan plots showing the results of single-probe CNV association testing. At a Bonferroni P value cutoff (blue line) of $P < 8.71E-7$ for the all EOC cases (based on 57 432 tests) and $P < 8.56E-7$ for HGSOC cases only (based on 58 382 tests) identified statistically significant probes at the BRCA1 gene locus. Evidence of several additional risk associations with a Bonferroni P value cutoff of $P < 5E-4$, including associations at intergenic sites, are also shown. B) Manhattan plot displaying results of common CNV analysis. At a Bonferroni P value cutoff of $P < 2.09E-6$ based on 23 960 tag SNPs included in the lookup, we identified statistically significant SNPs at 4 loci. At these loci, there are common CNVs in high linkage disequilibrium with GWAS SNPs that may account for some of the variation leading to differences in risk at that SNP. CNV = copy number variants; EOC = epithelial ovarian cancer; GWAS = genome-wide association studies; HGSOC = high-grade serous ovarian cancer; SNP = single nucleotide variants.

Table 4. GWAS loci with CNVs associated with EOC or HGSOC risk ($P < .05$)

Cytoband	rsID	GWAS P	LD block start	LD block end
NMOC loci				
3q28	rs9869209	6.61E-09	190508818	192626025
5p15.33	rs4449583	2.76E-21	982137	2132328
10p12.31	rs7084454	1.86E-12	19427949	22483354
17q21.31 ^a	rs146596949	1.26E-51	41743558	43694719
17q21.31 ^a	rs575499584	4.12E-18	44979537	47798656
17q21.32	rs12946636	9.92E-25	47798656	49440038
19p13.11	rs4808075	5.76E-26	16263605	18299052
HGSOC associated loci				
4q13.2/4q13.3	rs4149419	2.66E-08	67989047	70183435
5p15.33	rs4449583	1.09E-19	982137	2132328
9q31.1	rs2122577	2.94E-09	103205694	104819468
9p22.1/9p21.3	rs7851336	2.54E-10	18661053	20463536
10p12.31	rs7084454	1.48E-09	19427949	22483354
13q13.1	rs11571815	4.32E-09	31727678	33202766
15q26.1	rs76119208	3.36E-09	89932319	91621162
17q12	rs11657964	2.63E-12	36141651	38653091
17q21.31	rs146596949	3.11E-56	41743558	43694719
17q21.31	rs575499584	1.69E-19	44979537	47798656
17q21.32	rs12946636	5.54E-19	47798656	49440038
19p13.11	rs56069439	8.41E-38	16263605	18299052

^aBRCA1 locus. CNV = copy number variants; GWAS = genome-wide association analysis; LD = linkage disequilibrium; HGSOC = high-grade serous ovarian cancer; NMOC = all nonmucinous ovarian cancer.

17 000 controls to characterize CNVs and evaluate their associations with EOC and HGSOC risk. This study represents the largest to evaluate the contribution of CNVs to ovarian cancer risk

performed to date. Two previous studies failed to find strong evidence of CNVs associated with EOC risk (34,35). Both prior studies focused on common CNVs (>1% frequency), whereas we focused

Table 5. HRC tagSNPs in LD with known common CNVs from 1000G that are statistically significantly associated with EOC risk (hg38)^a

tagSNP	Chr	Position	Effect allele	Noneffect allele	CNV start	CNV end	CNV type	Length (bp)	P_{NMOC}	No. sig tagSNPs	P_{HGSOC}	No. sig tagSNPs
rs10962691	9	16915107	G	C	16905594	16905924	Deletion	330	1.48E-50	3	4.38E-68	3
rs17689104	17	45705126	G	A	45753354	45753478	Deletion	124	3.12E-12	152	9.59E-15	152
rs17688922	17	45701985	A	G	45753354	45753478	Deletion	124	3.17E-12	152	9.55E-15	152
rs8080583	17	46085231	A	C	46009357	46009595	Deletion	238	1.85E-12	179	2.32E-15	181
rs8080583	17	46085231	A	C	46146541	46146855	Deletion	314	1.85E-12	179	2.32E-15	181

^a1000G = 1000 Genomes project; CNV = copy number variant; EOC = epithelial ovarian cancer; HGSOC = high-grade serous ovarian cancer; HRC = Haplotype Reference Consortium; LD = linkage disequilibrium; NMOC = all nonmucinous ovarian cancer; SNP = single nucleotide polymorphism.




Figure 3. Enrichment of EOC statistically significant CNVs ($P < .05$) in functional biofeatures in ovarian cancer-related cell types. EOC risk CNVs are statistically significantly enriched in insulators across all ovarian cancer-relevant histotype consensus groups. The total number of risk CNVs in each biofeature per histotype grouping can be found in [Supplementary Table 11](#) (available online). Abbreviations for histotypes are as follows: CCOC = clear cell ovarian cancer; EEC = endometriosis (precursor cell type); FT = fallopian tube secretory epithelial cells (precursor cell type); HGSOC = high-grade serous ovarian cancer; IOSE = immortalized ovarian surface epithelium (precursor cell type); LGSOC = low-grade serous ovarian cancer; MOC = mucinous ovarian cancer. CNV = copy number variants; EOC = epithelial ovarian cancer.

on rare CNVs, and this, along with the large difference in sample size, likely contributed to the lack of replication. Using gene burden analyses, we identified highly statistically significant deletions and duplications at the *BRCA1* gene locus and confirmed these findings using single probe association testing. We also found evidence of CNV risk associations at 2 other EOC susceptibility loci: *RAD51C* and *BRCA2*. A subset of EOC cases and controls included in this study have been previously sequenced to identify germline *BRCA1* ($n = 89$), *BRCA2* ($n = 106$), and *RAD51C* ($n = 8$) coding variants (48,49,53), and none of the 203 patients carrying a pathogenic mutation in any of these genes also harbored a predicted CNV in these genes. As single nucleotide variants (SNVs) and CNVs are rare in these genes, we expect patients with concurrent pathogenic SNVs and CNVs to be extremely rare. For all 3 loci, EOC risk estimates were stronger when we restricted the analyses to HGSOC cases only, consistent with previous studies indicating that mutations in these genes are more strongly associated with HGSOC.

Prior studies report pathogenic *BRCA1* coding sequence mutations at a frequency of 5.3% in HGSOC (48), and we identified CNVs at the *BRCA1* gene locus in 1.1% of HGSOC cases, suggesting CNVs represent a substantial contribution to the overall prevalence of *BRCA1* mutations in HGSOC cases. Previous candidate studies identified pathogenic deletions and rearrangements involving *BRCA1*, *BRCA2*, and moderate-risk CNVs in high-risk hereditary breast and ovarian cancer (HBOC) families where a mutation was not identified in clinical testing (54-61),

and we identified deletions and duplications overlapping previously reported CNVs, such as deletions in exon 2-9 of *RAD51C* or deletions in exons 14-16 of *BRCA2* (55,57). *BRCA2* CNV mutations are rarer than *BRCA1* CNVs, however, they are still estimated to account for up to 8% of germline *BRCA2* mutations (47,62-67). The contribution of CNVs to *BRCA1* varies greatly depending on population, with CNVs being 3% of *BRCA1* mutations in South African HBOC families (68) and 27%-36% of *BRCA1* mutations in Dutch HBOC families (46,69). CNVs account for a smaller proportion of *BRCA2* carriers comparatively, with a Danish study of HBOC families finding *BRCA1* CNVs in 12.5% of all *BRCA1* carriers but only 2% of *BRCA2* carriers (62). Most estimates of contribution are from screening individuals in hereditary breast and ovarian cancer families rather than all ovarian cancer cases, as in our study, which may partially account for the fewer CNVs seen in our data. It is likely that *BRCA2* and *RAD51C* contain clinically relevant CNVs but also that other moderate-risk genes with CNVs or structural variants would be found in a cohort with sufficient sample size and a sensitive detection method. It is more difficult to find estimates of CNV contribution to these genes in nonfamilial studies. In a study of 376 000 participants undergoing genetic testing, 12.7% of pathogenic variants in *BRCA1*, 1.9% of pathogenic variants in *BRCA2*, and 21.1% of pathogenic variants in *RAD51C* were large rearrangements (70). The percent of all ovarian cancer patients with a CNV vs SNV as their pathogenic mutation in these genes is not currently available.

CNV association analyses also identified novel candidate ovarian cancer susceptibility genes, including *FBLIM1*, *HAS3*, and *LSP1*. Germline whole-exome sequencing studies have previously implicated *FBLIM1* as a putative susceptibility gene in HGSOC (71). The gene is differentially expressed between benign and malignant murine ovarian surface epithelial cells and is dysregulated in ovarian cancers (72,73). *LSP1* is a candidate breast cancer susceptibility gene and may interact multiplicatively to increase breast cancer risk for *BRCA2* mutation carriers (16,74-76), and the *HAS3* gene may also be associated with the development of chemoresistant ovarian cancer (77,78).

Rare variant association analysis detected a number of suggestive associations for individual variants. Only the *BRCA1* variants with large effect sizes ($OR > 10$) passed the multiple-testing P value threshold. If associations for rare CNVs are to be confirmed, a key question is the magnitude of effect sizes we should expect for CNVs outside the known genes. Sample size requirements scale linearly with decreasing minor allele frequency but quadratically for decreasing odds ratios ($1/|OR - 1|$) (79). When compared with associations for common noncoding SNPs, the possible associations in this analysis have large odds ratios ranging from 0.15 to 0.76 and from 1.83 to 4.44. It is plausible that evolutionary younger rare variants not yet removed by negative selection can have a stronger biological effect than older common variants.

There is also some evidence from sequencing studies that non-coding SVs such as CNVs are more likely to have a stronger biological effect than SNVs. For example, Abel et al. (80) calculated that each individual carried 122 rare variants (63% SNVs, 20% indels, 17% SVs) predicted to be deleterious, and given their relative frequency, SVs are 841-fold more likely to be deleterious than rare SNVs and 341-fold more than rare indels. We estimate that the probe coverage on the OncoArray allows us to detect up to 10% of the deletions and 25% of the duplications identified by the 1000G in the 0.05% to 1% frequency range in the European population.

The most statistically significantly risk-associated deletion impacts part of the long noncoding RNA *LINC01194* ($n = 137$, $OR = 0.53$; $P = .0007$). There is some evidence for an oncogenic role for *LINC01194* from expression analyses in colorectal tumors (81) and prostate tumors and cancer cell lines (82). The strongest duplication association was observed in an intron at the start of the *DCDC2* gene ($n = 90$, $OR = 0.45$; $P = .0004$). Interestingly, the reverse strand of this gene encodes *KAAG1*, which has been identified as an antigen expressed on the surface of cancer cells in a high proportion of ovarian tumors (83). The strongest result in the HGSOCA analysis is for a duplication covering the first exon of the *LSP1* gene ($n = 37$, $OR = 3.10$; $P = .0008$) (71).

We observed enrichment of risk-associated CNVs at EOC risk loci identified by GWAS. A wide variety of genetic variation, including SNVs and CNVs at GWAS loci, may contribute cumulatively to observed signal through aggregation by LD, and CNV analysis may implicate candidate genes for further functional analysis. Most EOC-risk associated variants identified by GWAS lie in noncoding DNA regions. In our study, noncoding risk-associated CNVs were enriched in weak promoters and insulators (bound CTCF motifs), suggesting they mediate gene expression through their interaction with regulatory elements and the 3-dimensional structure of the genome. Studies have shown germline risk variants and CNVs altering CTCF sites underlie some human diseases (84,85).

We have used genome-wide analysis to identify rare CNVs associated with ovarian cancer risk, including at known EOC susceptibility gene loci *BRCA1*, *BRCA2*, and *RAD51C*. Given the frequency at which we detected these CNVs, it may be appropriate to expand the content of genetic risk assessment panels for breast and ovarian cancer to universally include coverage of CNVs at *BRCA1*, *BRCA2*, and *RAD51C* as likely pathogenic variants where such testing is not already standard (86). CNVs likely represent a missing fraction of heritability for ovarian cancer at known susceptibility genes and as independent risk variants. Evaluating the frequency of CNVs in larger EOC case-control populations and with whole genome sequencing on a population scale is warranted to improve our understanding of the genetic architecture for EOC.

Funding

This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health (5T32GM118288-03); the CSMC Precision Health Initiative; and the Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation. Supported in part by the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07); the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112); the Wellcome Trust (076113); the National Cancer Institute and National Human Genome Research Institute (dbGap accession number phs000178.v8.p7); the U.S. National Institutes of Health (CA1X01HG007491-01 (CIA), U19-

CA148112 (TAS), R01-CA149429 (CMP) and R01-CA058598 (MTG); Canadian Institutes of Health Research (MOP-86727 (LEK); the Ovarian Cancer Research Fund (AB); a European Commission's Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175); the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729); National Health & Medical Research Council of Australia (199600, 400413 and 400281); Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182); Ovarian Cancer Australia and the Peter MacCallum Foundation; ELAN Funds of the University of Erlangen-Nuremberg; National Kankerplan; Breast Cancer Now, Institute of Cancer Research; the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) (ULTR000445 - the 1S10RR025141-01 instrumentation award and Vanderbilt CTSA grant); the European Commission (DG-SANCO); the International Agency for Research on Cancer; Danish Cancer Society (Denmark) (EMC 2014-6699); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Éducation Nationale; Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid; German Cancer Research Center (DKFZ); Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS); Netherlands Cancer Registry (NKR); LK Research Funds; Dutch Prevention Funds; Dutch ZON (Zorg Onderzoek Nederland); World Cancer Research Fund (WCRF); Statistics Netherlands (the Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia; Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom); German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ); U.S. National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001); intramural funding; Rudolf-Bartling Foundation; Helsinki University Hospital Research Fund; University of Pittsburgh School of Medicine Dean's Faculty Advancement Award (F. Modugno); Department of Defense (DAMD17-02-1-0669); NCI (K07-CA080668, R01-CA95023, P50-CA159981 MO1-RR000056 R01-CA126841); intramural funding from the Rudolf-Bartling Foundation; ERC-2011-AdG 294576-risk factors cancer, Swedish Cancer Society, Swedish Research Council, Beta Kamprad Foundation; the National Cancer Institute (R01-CA61107), the Danish Cancer Society, Copenhagen, Denmark (94 222 52); the Mermaid I project; National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; VicHealth and Cancer Council Victoria, Cancer Council Victoria, National Health and

Medical Research Council of Australia (NHMRC) (209057, 251533, 396414, and 504715); DOD Ovarian Cancer Research Program (W81XWH-07-0449); Moffitt Cancer Center; Merck Pharmaceuticals; the state of Florida; Hillsborough County; the city of Tampa; National Institutes of Health (R01-CA76016); the Department of Defense (DAMD17-02-1-0666); National Institutes of Health (R01-CA54419 and P50-CA105009); Department of Defense (W81XWH-10-1-02802. UM1 CA186107, P01 CA87969, R01 CA49449, R01-CA67262, UM1 CA176726); Radboud University Medical Centre; Canadian Institutes of Health Research grant (MOP-86727); National Institutes of Health/National Cancer Institute 1 (R01CA160669-01A1); Intramural Research Program of the National Cancer Institute; Pomeranian Medical University; Cancer Research UK (C490/A10119 C490/A10124); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES049033); The Swedish Cancer Foundation and the Swedish Research Council (VR 2017-00644); National Institutes of Health (R01-CA106414-A2); American Cancer Society (CRTG-00-196-01-CCE); Department of Defense (DAMD17-98-1-8659); Celma Mastry Ovarian Cancer Foundation; National Institutes of Health (R01-CA058860); the Lon V Smith Foundation (LVS-39420); The Eve Appeal (The Oak Foundation); National Institute for Health Research University College London Hospitals Biomedical Research Centre and MRC core funding (MR_UU_12023); P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200); National Science Centre (N N301 5645 40); The Maria Sklodowska-Curie Memorial Cancer Centre; and the Institute of Oncology, Warsaw, Poland. The Nurses' Health Study (NHS) was supported by the National Institutes of Health (UM1 CA186107, P01 CA87969, R01 CA49449) and the NHS II was supported by the National Institutes of Health (U01 CA176726, R01 CA67262). Joe Dennis is supported by the CanRisk Cancer Research UK programme grant: PPRPGM-Nov20\100002 and by the Confluence project which is funded with intramural funds from the National Cancer Institute Intramural Research Programme, National Institutes of Health.

Notes

Role of the funder: The funding agencies had no role in the conceptualization of the study; collection or analysis of the data; or drafting and editing of the manuscript, or decision to submit it for publication.

Disclosures: Matthias W. Beckmann conducts research funded by Amgen, Novartis, and Pfizer. Peter A. Fasching conducts research funded by Amgen, Novartis, and Pfizer, and he received Honoraria from Roche, Novartis, and Pfizer. Usha Menon has stock ownership in Abcodia Ltd. AHE, who is a JNCI Associate Editor and co-author on this article, was not involved in the editorial review or decision to publish the manuscript. The remaining authors have no conflicts of interest to disclose.

Author contributions: Conceptualization: AAD, JD, JPY, PDPP, DFE, SAG, MRJ. Data curation: AAD, JD, JPY, PCP, SGC, ALR, JTP, BDD, SC, FSD. Formal Analysis: AAD, JD, JPY. Funding acquisition: HAC, AB,

RB, GCT, LSC, TD, ELG, MTG, JG, LAK, SKK, JK, DL, NDL, UM, RLM, FM, ANM, HO, CLP, SJR, ER, MJR, IR, DPS, JMS, RS, KLT, SST, DVE, PMW, NW, AW, AHW, PDPP, SAG. Investigation: AAD, JD, JPY, PDPP, DFE, SAG, MRJ. Methodology: AAD, JD, JPY, PDPP, DFE, SAG, MRJ. Project administration: MJR, PDPP, DFE, SAG, MRJ. Resources: AADV, JD, JPT, PCP, SGC, ALR, JTP, BDD, SC, FSD, KKHA, HAC, NNA, MWB, ABF, AB, NVB, JDB, RB, IC, JCC, GCT, LSC, ADF, JAD, TD, DME, AHE, PAF, RTE, GGG, ELG, MTG, JG, NH, MATH, CH, DGH, AJ, PK, SK, BYK, EKK, LAK, SKK, JK, ML, DL, NDL, JL, TM, UM, RLM, FM, ANM, KBM, HN, KO, HO, CLP, TP, SJR, ER, MJR, IR, DPS, JMS, VWS, WS, HS, RS, KLT, PJT, LT, SST, EVN, DVE, PMW, NW, ASW, AW, AHW, AZ, MLF, KL, PDPP, DFE, SAG, MRJ. Software: AADV, JD, JPT, PCP, SGC. Supervision: PDPP, DFE, SAG, MRJ. Validation: AAD, JD, JPY, MRJ. Visualization: AAD, JD, MRJ. Writing—original draft: AAD, JD, JPY, PDPP, DFE, SAG, MRJ. Writing—review & editing: AADV, JD, JPT, PCP, SGC, ALR, JTP, BDD, SC, FSD, KKHA, HAC, NNA, MWB, ABF, AB, NVB, JDB, RB, IC, JCC, GCT, LSC, ADF, JAD, TD, DME, AHE, PAF, RTE, GGG, ELG, MTG, JG, NH, MATH, CH, DGH, AJ, PK, SK, BYK, EKK, LAK, SKK, JK, ML, DL, NDL, JL, TM, UM, RLM, FM, ANM, KBM, HN, KO, HO, CLP, TP, SJR, ER, MJR, IR, DPS, JMS, VWS, WS, HS, RS, KLT, PJT, LT, SST, EVN, DVE, PMW, NW, ASW, AW, AHW, AZ, MLF, KL, PDPP, DFE, SAG, MRJ.

Acknowledgements: We thank the study participants, doctors, nurses, clinical and scientific collaborators, health-care providers, and health information sources who have contributed to the many studies contributing to this manuscript. The Australian Ovarian Cancer Study (AOCS) also acknowledges the cooperation of the participating institutions in Australia and the contribution of the study nurses, research assistants, and all clinical and scientific collaborators. The complete AOCS Group can be found at www.aocstudy.org. We would like to thank all of the women who participated in this research program. The datasets used for the analyses described were in part obtained from Vanderbilt University Medical Center's BioVU. The authors would like to thank all members and investigators of the Rotterdam Ovarian Cancer Study. Some cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. The authors would like to thank The Total Cancer Care Protocol and the Collaborative Data Services and Tissue Core Facilities at the H. Lee Moffitt Cancer Center & Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center (P30-CA076292), Merck Pharmaceuticals, and the state of Florida. The Nurses' Health Study and Nurses' Health Study II thank the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY.

Disclaimers: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Prior presentations: Some of the content has been presented publicly as a poster at the 69th Annual Meeting of the American Society for Human Genetics in 2019 in Houston on October 17, 2019 (Abstract #985). The abstract can be accessed here: <https://www.ashg.org/wp-content/uploads/2019/10/ASHG-2019-poster-abstracts.pdf>.

Data Availability

All data used and code developed for these analyses are available on Github at <https://github.com/Jones-Lab-CSMC/OCAC-Oncoarray-CamGNV>.

References

- Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. *Mol Oncol*. 2009;3(2):138-150. doi:10.1016/j.molonc.2009.02.001.
- Ramus SJ, Song H, Dicks E, et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. *J Natl Cancer Inst*. 2015;107(11):djv214. doi:10.1093/jnci/djv214.
- Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. *JAMA Oncol*. 2016;2(4):482-490. doi:10.1001/jamaoncol.2015.5495.
- Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci USA*. 2011;108(44):18032-18037. doi:10.1073/pnas.1115052108.
- Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. *Nat Genet*. 2011;43(11):1104-1107. doi:10.1038/ng.955.
- Phelan CM, Kuchenbaecker KB, Tyrer JP, et al.; for the OPAL study group. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet*. 2017;49(5):680-691. doi:10.1038/ng.3826.
- Pharoah PDP, Tsai Y-Y, Ramus SJ, et al.; for the Australian Ovarian Cancer Study Group. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet*. 2013;45(4):362-370.e1. doi:10.1038/ng.2564.
- Song H, Ramus SJ, Tyrer J, et al.; for the Australian Cancer (Ovarian) Study. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet*. 2009;41(9):996-1000. doi:10.1038/ng.424.
- Goode EL, Chenevix-Trench G, Song H, et al.; for the Ovarian Cancer Association Consortium (OCAC). A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet*. 2010;42(10):874-879. doi:10.1038/ng.668.
- Permeth-Wey J, Lawrenson K, Shen HC, et al.; for the Consortium of Investigators of Modifiers of BRCA1/2. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat Commun*. 2013;4:1627. doi:10.1038/ncomms2613.
- Shen H, Fridley BL, Song H, et al.; for the Australian Cancer Study. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nat Commun*. 2013;4:1628. doi:10.1038/ncomms2629.
- Bojesen SE, Pooley KA, Johnatty SE, et al.; for the Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO). Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet*. 2013;45(4):371-384.e1. doi:10.1038/ng.2566.
- Kuchenbaecker KB, Ramus SJ, Tyrer J, et al.; for the EMBRACE. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet*. 2015;47(2):164-171. doi:10.1038/ng.3185.
- Kelemen LE, Lawrenson K, Tyrer J, et al.; for the Ovarian Cancer Association Consortium. Genome-wide significant risk associations for mucinous ovarian carcinoma. *Nat Genet*. 2015;47(8):888-897. doi:10.1038/ng.3336.
- Kar SP, Beesley J, Amin Al Olama A, et al.; for the ABCTB Investigators. Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. *Cancer Discov*. 2016;6(9):1052-1067. doi:10.1158/2159-8290.CD-15-1227.
- Couch FJ, Wang X, McGuffog L, et al.; for the CIMBA. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet*. 2013;9(3):e1003212. doi:10.1371/journal.pgen.1003212.
- Bolton KL, Tyrer J, Song H, et al.; for the Ovarian Cancer Association Consortium. Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet*. 2010;42(10):880-884. doi:10.1038/ng.666.
- Pearce CL, Stram DO, Ness RB, et al. Population distribution of lifetime risk of ovarian cancer in the United States. *Cancer Epidemiol Biomarkers Prev*. 2015;24(4):671-676. doi:10.1158/1055-9965.EPI-14-1128.
- Lu Y, Ek WE, Whiteman D, et al. Most common "sporadic" cancers have a significant germline genetic component. *Hum Mol Genet*. 2014;23(22):6112-6118. doi:10.1093/hmg/ddu312.
- Brandler WM, Antaki D, Gujral M, et al. Frequency and complexity of de novo structural mutation in autism. *Am J Hum Genet*. 2016;98(4):667-679. doi:10.1016/j.ajhg.2016.02.018.
- Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. *Nature*. 2006;444(7118):444-454. doi:10.1038/nature05329.
- Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. *Nat Methods*. 2012;9(3):215-216. doi:10.1038/nmeth.1906.
- Long J, Delahanty RJ, Li G, et al. A common deletion in the APOBEC3 genes and breast cancer risk. *J Natl Cancer Inst*. 2013;105(8):573-579. doi:10.1093/jnci/djt018.
- Kuusisto KM, Akinrinade O, Vihinen M, Kankuri-Tammilehto M, Laasanen S-L, Schleutker J. Copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer. *PLoS One*. 2013;8(8):e71802. doi:10.1371/journal.pone.0071802.
- Kumaran M, Cass CE, Graham K, et al. Germline copy number variations are associated with breast cancer risk and prognosis. *Sci Rep*. 2017;7(1):14621. doi:10.1038/s41598-017-14799-7.
- Komatsu A, Nagasaki K, Fujimori M, Amano J, Miki Y. Identification of novel deletion polymorphisms in breast cancer. *Int J Oncol*. 2008;33(2):261-270. doi:10.3892/ijo.00000005.
- Walker LC, Pearson JF, Wiggins GAR, Giles GG, Hopper JL, Southey MC. Increased genomic burden of germline copy number variants is associated with early onset breast cancer. Australian Breast Cancer Family Registry. *Breast Cancer Res*. 2017;19(1):30. doi:10.1186/s13058-017-0825-6.
- Pylikäs K, Vuorela M, Otsukka M, Kallioniemi A, Jukkola-Vuorinen A, Winqvist R. Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network. *PLoS Genet*. 2012;8(6):e1002734. doi:10.1371/journal.pgen.1002734.
- de Jesús Ascencio-Montiel I, Pinto D, Parra EJ, Valladares-Salgado A, Cruz M, Scherer SW. Characterization of large copy number variation in Mexican type 2 diabetes subjects. *Sci Rep*. 2017;7(1):17105. doi:10.1038/s41598-017-17361-7.
- Bae JS, Cheong HS, Kim J-H, et al. The genetic effect of copy number variations on the risk of type 2 diabetes in a Korean population. *PLoS One*. 2011;6(4):e19091. doi:10.1371/journal.pone.0019091.
- Craddock N, Hurles ME, Cardin N, et al.; for the Wellcome Trust Case Control Consortium. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. *Nature*. 2010;464(7289):713-720. doi:10.1038/nature08979.
- Al-Sukhni W, Joe S, Lionel AC, et al. Identification of germline genomic copy number variation in familial pancreatic cancer. *Hum Genet*. 2012;131(9):1481-1494. doi:10.1007/s00439-012-1183-1.
- Collins RL, Brand H, Karczewski KJ, et al.; for the Genome Aggregation Database Consortium. A structural variation reference for medical and population genetics. *Nature*. 2020;581(7809):444-451. doi:10.1038/s41586-020-2287-8.
- Reid BM, Permeth JB, Chen YA, et al. Genome-wide analysis of common copy number variation and epithelial ovarian cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2019;28(7):1117-1126. doi:10.1158/1055-9965.EPI-18-0833.
- Fridley BL, Chalise P, Tsai Y-Y, et al. Germline copy number variation and ovarian cancer survival. *Front Genet*. 2012;3:142. doi:10.3389/fgene.2012.00142.
- Dennis J, Walker L, Tyrer J, Michailidou K, Easton DF. Detecting rare copy number variants from Illumina genotyping arrays with the CamCNV pipeline: segmentation of z-scores improves detection and reliability. *Genet Epidemiol*. 2021;45(3):237-248. doi:10.1002/gepi.12367.
- Tyrer JP, Guo Q, Easton DF, Pharoah PDP. The admixture maximum likelihood test to test for association between rare variants and disease phenotypes. *BMC Bioinformatics*. 2013;14:177. doi:10.1186/1471-2105-14-177.
- Gusev A, Lawrenson K, Lin X, et al.; for the Ovarian Cancer Association Consortium. A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants. *Nat Genet*. 2019;51(5):815-823. doi:10.1038/s41588-019-0395-x.
- Lu Y, Beeghly-Fadiel A, Wu L, et al. A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. *Cancer Res*. 2018;78(18):5419-5430. doi:10.1158/0008-5472.CAN-18-0951.
- Berisa T, Pickrell JK. Approximately independent linkage disequilibrium blocks in human populations. *Bioinformatics*. 2016;32(2):283-285. doi:10.1093/bioinformatics/btv546.
- Coetzee S. *Simon-Coetzee/Funcivar*; 2018. <https://github.com/Simon-Coetzee/Funcivar>.
- Jones MR, Peng P-C, Coetzee SG, et al.; for the Ovarian Cancer Association Consortium. Ovarian cancer risk variants are enriched in histotype-specific enhancers and disrupt transcription factor binding sites. *Am J Hum Genet*. 2020;107(4):622-635. doi:10.1016/j.ajhg.2020.08.021.
- Reyes ALP, Silva TC, Coetzee SG, et al. GENAVI: a shiny web application for gene expression normalization, analysis and visualization. *BMC Genomics*. 2019;20(1):745. doi:10.1186/s12864-019-6073-7.
- Handsaker RE, Korn JM, Nemes J, McCarroll SA. Discovery and genotyping of genome structural polymorphism by sequencing on a population scale. *Nat Genet*. 2011;43(3):269-276. doi:10.1038/ng.768.
- Mazoyer S. The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. *Am J Hum Genet*. 2000;67(1):207-212. doi:10.1086/302974.
- Petrij-Bosch A, Peelen T, van Vliet M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. *Nat Genet*. 1997;17(3):341-345. doi:10.1038/ng1197-341.
- Woodward AM, Davis TA, Silva AGS, Kirk JA, Leary JA; for the kConFab Investigators. Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families. *J Med Genet*. 2005;42(5):e31. doi:10.1136/jmg.2004.027961.
- Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. *Hum Mol Genet*. 2014;23(17):4703-4709. doi:10.1093/hmg/ddu172.
- Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. *J Clin Oncol*. 2015;33(26):2901-2907. doi:10.1200/JCO.2015.61.2408.
- Buckley MA, Woods NT, Tyrer JP, et al.; for the Ovarian Cancer Association Consortium. Functional analysis and fine mapping of the 9p22.2 ovarian cancer susceptibility locus. *Cancer Res*. 2019;79(3):467-481. doi:10.1158/0008-5472.CAN-17-3864.
- de Jong S, Chepelev I, Janson E, et al. Common inversion polymorphism at 17q21.31 affects expression of multiple genes in tissue-specific manner. *BMC Genomics*. 2012;13:458. doi:10.1186/1471-2164-13-458.

52. Koolen DA, Vissers LELM, Pfundt R, et al. A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. *Nat Genet.* 2006;38(9):999-1001. doi:10.1038/ng1853.
53. Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. *Am J Hum Genet.* 1999;65(4):1021-1029. doi:10.1086/302583.
54. Kerkhof J, Schenkel LC, Reilly J, et al. Clinical validation of copy number variant detection from targeted next-generation sequencing panels. *J Mol Diagn.* 2017;19(6):905-920. doi:10.1016/j.jmoldx.2017.07.004.
55. Boone PM, Soens ZT, Campbell IM, et al. Incidental copy-number variants identified by routine genome testing in a clinical population. *Genet Med.* 2013;15(1):45-54. doi:10.1038/gim.2012.95.
56. Scaglione GL, Concolino P, De Bonis M, et al. A whole germline BRCA2 gene deletion: how to learn from CNV in Silico analysis. *Int J Mol Sci.* 2018;19(4):961. doi:10.3390/ijms19040961.
57. Schmidt AY, Hansen TVO, Ahlborn LB, Jønson L, Yde CW, Nielsen FC. Next-generation sequencing-based detection of germline copy number variations in BRCA1/BRCA2: validation of a one-step diagnostic workflow. *J Mol Diagn.* 2017;19(6):809-816. doi:10.1016/j.jmoldx.2017.07.003.
58. Truty R, Paul J, Kennemer M, et al. Prevalence and properties of intragenic copy-number variation in Mendelian disease genes. *Genet Med.* 2019;21(1):114-123. doi:10.1038/s41436-018-0033-5.
59. Bozsik A, Pócsa T, Papp J, et al. Complex characterization of germline large genomic rearrangements of the BRCA1 and BRCA2 Genes in high-risk breast cancer patients—novel variants from a large national center. *Int J Mol Sci.* 2020;21(13):4650. doi:10.3390/ijms21134650.
60. Hirotsu Y, Ooka Y, Sakamoto I, Nakagomi H, Omata M. Simultaneous detection of genetic and copy number alterations in BRCA1/2 genes. *Oncotarget.* 2017;8(70):114463-114473. doi:10.18632/oncotarget.22962.
61. Nunziato M, Starnone F, Lombardo B, et al. Fast detection of a BRCA2 large genomic duplication by next generation sequencing as a single procedure: a case report. *Int J Mol Sci.* 2017;18(11):2487. doi:10.3390/ijms18112487.
62. Hansen TO, Jønson L, Albrechtsen A, Andersen MK, Ejlersen B, Nielsen FC. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families. *Breast Cancer Res Treat.* 2009;115(2):315-323. doi:10.1007/s10549-008-0088-0.
63. Gad S, Klinger M, Caux-Moncoutier V, et al. Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families. *J Med Genet.* 2002;39(11):817-821. doi:10.1136/jmg.39.11.817.
64. Lahti-Domenici J, Rapakko K, Pääkkönen K, et al. Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families. *Cancer Genet Cytogenet.* 2001;129(2):120-123. doi:10.1016/s0165-4608(01)00437-x.
65. Peelen T, van Vliet M, Bosch A, et al. Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. *Br J Cancer.* 2000;82(1):151-156. doi:10.1054/bjoc.1999.0892.
66. Agata S, Dalla Palma M, Callegaro M, et al. Large genomic deletions inactivate the BRCA2 gene in breast cancer families. *J Med Genet.* 2005;42(10):e64. doi:10.1136/jmg.2005.032789.
67. Peixoto A, Santos C, Rocha P, et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. *Breast Cancer Res Treat.* 2009;114(1):31-38. doi:10.1007/s10549-008-9978-4.
68. Sluiter MD, van Rensburg EJ. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. *Breast Cancer Res Treat.* 2011;125(2):325-349. doi:10.1007/s10549-010-0817-z.
69. Hogervorst FBL, Nederlof PM, Gille JJP, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. *Cancer Res.* 2003;63(7):1449-1453.
70. Mancini-DiNardo D, Judkins T, Kidd J, et al. Detection of large rearrangements in a hereditary pan-cancer panel using next-generation sequencing. *BMC Med Genomics.* 2019;12(1):138. doi:10.1186/s12920-019-0587-3.
71. Subramanian DN, Zethoven M, McInerney S, et al. Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes. *Nat Commun.* 2020;11(1):1640. doi:10.1038/s41467-020-15461-z.
72. Creekmore AL, Silkworth WT, Cimino D, Jensen RV, Roberts PC, Schmelz EM. Changes in gene expression and cellular architecture in an ovarian cancer progression model. *PLoS One.* 2011;6(3):e17676. doi:10.1371/journal.pone.0017676.
73. Emmanuel C, Gava N, Kennedy C, et al.; for the Australian Ovarian Cancer Study Group. Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. *PLoS One.* 2011;6(3):e17617. doi:10.1371/journal.pone.0017617.
74. Huijts PEA, Vreeswijk MPG, Kroeze-Jansema KHG, et al. Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. *Breast Cancer Res.* 2007;9(6):R78. doi:10.1186/bcr1793.
75. Gates MA, Tworoger SS, Terry KL, et al. Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations. *Int J Cancer.* 2009;124(3):729-733. doi:10.1002/ijc.23924.
76. Antoniou AC, Sinilnikova OM, McGuffog L, et al.; for the CIMBA. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet.* 2009;18(22):4442-4456. doi:10.1093/hmg/ddp372.
77. Lokman NA, Price ZK, Hawkins EK, Macpherson AM, Oehler MK, Ricciardelli C. 4-Methylumbelliferone inhibits cancer stem cell activation and overcomes chemoresistance in ovarian cancer. *Cancers (Basel).* 2019;11(8):1187. doi:10.3390/cancers11081187.
78. Ricciardelli C, Ween MP, Lokman NA, Tan IA, Pyragius CE, Oehler MK. Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. *BMC Cancer.* 2013;13:476. doi:10.1186/1471-2407-13-476.
79. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. *Nature.* 2009;461(7265):747-753. doi:10.1038/nature08494.
80. Abel HJ, Larson DE, Regier AA, et al.; for the NHGRI Centers for Common Disease Genomics. Mapping and characterization of structural variation in 17,795 human genomes. *Nature.* 2020;583(7814):83-89. doi:10.1038/s41586-020-2371-0.
81. Wang X, Liu Z, Tong H, et al. Linc01194 acts as an oncogene in colorectal carcinoma and is associated with poor survival outcome. *Cancer Manag Res.* 2019;11:2349-2362. doi:10.2147/CMAR.S189189.
82. Song HR, Guo XB, Duan Y, Meng HY, Wang ZY. PAX5-induced upregulation of LINC01194 exerts oncogenic properties by regulating GOLPH3 expression via miR-486-5p in prostate cancer. *Eur Rev Med Pharmacol Sci.* 2021;25(6):2528-2541. doi:10.26355/eurev.202103.25416.
83. Zammarchi F, Bertelli F, Havenith K, Kirby I, Chivers S, Berkel P. V. Abstract 234: Pre-clinical characterization of 3A4-PL1601, a novel pyrrolo-benzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies. In: *Experimental and Molecular Therapeutics.* Am Assoc Cancer Res. 2019;79(suppl 13):234-234. doi:10.1158/1538-7445.AM2019-234.
84. Han L, Zhao X, Benton ML, et al.; for the CommonMind Consortium. Functional annotation of rare structural variation in the human brain. *Nat Commun.* 2020;11(1):2990. doi:10.1038/s41467-020-16736-1.
85. Laplana M, Royo JL, García LF, Aluja A, Gomez-Skarmeta JL, Fibla J. SIRPB1 copy-number polymorphism as candidate quantitative trait locus for impulsive-disinhibited personality. *Genes Brain Behav.* 2014;13(7):653-662. doi:10.1111/gbb.12154.
86. Casilli F, Di Rocco ZC, Gad S, et al. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. *Hum Mutat.* 2002;20(3):218-226. doi:10.1002/humu.10108.